SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Dr Reddy's Laboratories to ink pact with Fujifilm by June 2012

28 Mar 2012 Evaluate

Dr Reddy's Laboratories, India’s second largest pharma company is likely to sign a definitive agreement with Japan-based Fujifilm by June 2012. This joint venture will develop and produce generic drugs for the Japanese market. It will take 2-3 years for the company to come out with products.

The company has to obtain product approvals from Japanese authorities before the launch. It had announced the partnership in July, 2011. As part of the JV agreement company is expected to set up a manufacturing facility. This JV will design products that fit the specific requirements of the Japanese market, aiming to deliver reliable, high quality generic drugs enabling the growth of generic drug market.

As per the agreement the new joint venture will have 51% stake owned by Fujifilm and 49% stake owned by Dr Reddy's. Making use of both Fujifilm's advanced quality control technologies and DRL's expertise in cost competitive production technologies for active pharmaceutical ingredients and formulations, the new company will develop, manufacture and promote competitive and high quality generic drugs.

Dr. Reddys Lab Share Price

1279.70 -13.55 (-1.05%)
11-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1872.40
Dr. Reddys Lab 1279.70
Cipla 1304.70
Zydus Lifesciences 956.65
Lupin 2245.65
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×